{"id":8588,"date":"2022-11-22T08:16:00","date_gmt":"2022-11-22T13:16:00","guid":{"rendered":"https:\/\/vetanco.com\/en\/?p=8588"},"modified":"2026-03-10T09:35:50","modified_gmt":"2026-03-10T13:35:50","slug":"vedevax-block","status":"publish","type":"post","link":"https:\/\/vetanco.com\/en\/vedevax-block\/","title":{"rendered":"Vedevax Block Vaccine finalist for the Empretec Award"},"content":{"rendered":"\n\n\n

The world\u2019s first targeted vaccine against the Bovine Viral Diarrhea Virus (BVDV), developed by Bioinnovo, was one of 4 finalists in its category among around 1,000 projects submitted at the 13th<\/sup> edition of the Pioneering Solutions Contest<\/a> from Banco Naci\u00f3n, aimed at SMEs and enterprises.<\/em><\/p>\n\n\n\n

Aiming to enhance projects targeted at improving people\u2019s lives, contributing to the development of communities, upgrading productive systems, creating or embracing technologies that alleviate adverse effects in the environment and generating inclusive processes for the most disadvantaged social groups, Banco Naci\u00f3n<\/a> organized the Empretec<\/a> contest for pioneering solutions. During its 13th<\/sup> edition, the development of the Vedevax Block<\/a> vaccine turned out to be one of the four finalists in the \u2018Pioneering Solutions Targeted at the Production System<\/em>\u2019 category, after a selection process consisting of different stages among a total of around 1,000 submitted projects.<\/p>\n\n\n\n

\u2018The mention obtained is the result of the long process of creating the first recombinant targeted vaccine against Bovine Viral Diarrhea (BVDV) at Bioinnovo SA<\/a>, a company constituted by INTA<\/a> and Vetanco<\/em>\u2019, said Andr\u00e9s Wigdorovitz, manager of IncuINTA.<\/p>\n\n\n\n

\u2018It was a process that grew with challenges, registrations and learning, although we still have much to learn and develop<\/em>\u2019, Wigdorovitz reflected. \u2018Now we\u2019re approaching a new stage, the internationalization of this vaccine with its registrations and events abroad.<\/em>\u2019<\/p>\n\n\n\n

\u2018We thought it was important to participate in this contest of national impact targeted at enterprises and project development, where the proposal is also part of a training we took part in<\/em>\u2019, said Demian Bellido, Vedevax project\u2019s lead researcher.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

On his part, Jorge Winokur, Bioinnovo\u2019s manager, has said they plan to increment participation in scientific events and business meetings abroad to offer the product to potential adherents of this technology.<\/p>\n\n\n\n

About Vedevax Block<\/strong><\/p>\n\n\n\n

It is the world\u2019s first targeted subunit vaccine against Bovine Viral Diarrhea. A disease that causes substantial losses because it affects cattle all around the world, of all breeds, in all development stages, affecting reproduction rates since it is the main causal agent of temporary infertility.<\/p>\n\n\n\n

The vaccine has a positive impact on controlling the virus, increasing the calf production of an industry that supplies both the local and international markets. \u2019It allows us to obtain antibody titers from live vaccines, but without the risks\u2019<\/em>, said Andr\u00e9s Wigdorovitz, a scientific leader at Bioinnovo SA.<\/p>\n\n\n\n

Attenuated or live vaccines are prohibited in Argentina for safety reasons. The country prides itself on an exceptional sanitary status without the presence of many diseases, which enhances the exportation of meat, its direct by-products like whey and milk powder, and its indirect ones like vaccines and processed food. Therefore it is of the upmost importance to maintain said sanitary status.<\/p>\n\n\n\n

\u2018This encouraged the development of Vedevax Block, which has the capacity to combine the potency of the live vaccines with the safety of inactivated vaccines\u2014 a journey that\u2019s only just begun<\/em>\u2019, stated Wigdorovitz.<\/p>\n","protected":false},"excerpt":{"rendered":"

The world\u2019s first targeted vaccine against the Bovine Viral Diarrhea Virus (BVDV), developed by Bioinnovo, was one of 4 finalists in its category among around 1,000 projects submitted at the 13th edition of the Pioneering Solutions Contest from Banco Naci\u00f3n, aimed at SMEs and enterprises. Aiming to enhance projects targeted at improving people\u2019s lives, contributing to the development […]\n","protected":false},"author":8,"featured_media":8590,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26,28],"tags":[51,53,21,23,52,20,24,18],"class_list":["post-8588","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-awards","category-news","tag-banco-nacion","tag-bioinnovo-sa","tag-bovine-viral-diarrhea-virus","tag-bvdv","tag-empretec","tag-inta","tag-vedevax-block","tag-vetanco"],"yoast_head":"\nVedevax Block Vaccine finalist for the Empretec Award - Vetanco United States<\/title>\n<meta name=\"description\" content=\"The world\u2019s first targeted vaccine against the Bovine Viral Diarrhea Virus (BVDV), was one of 4 finalists in its category.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vetanco.com\/en\/vedevax-block\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vedevax Block Vaccine finalist for the Empretec Award - Vetanco United States\" \/>\n<meta property=\"og:description\" content=\"The world\u2019s first targeted vaccine against the Bovine Viral Diarrhea Virus (BVDV), was one of 4 finalists in its category.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vetanco.com\/en\/vedevax-block\/\" \/>\n<meta property=\"og:site_name\" content=\"Vetanco United States\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-22T13:16:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-10T13:35:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vetanco.com\/en\/wp-content\/uploads\/2024\/09\/Bioinnovo-finalista-premio-Empretec-1024x768-2.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"julian\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"julian\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/vetanco.com\/en\/vedevax-block\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/vetanco.com\/en\/vedevax-block\/\"},\"author\":{\"name\":\"julian\",\"@id\":\"https:\/\/vetanco.com\/en\/#\/schema\/person\/46afb38cfab0fe11bf52a9ded679bfcd\"},\"headline\":\"Vedevax Block Vaccine finalist for the Empretec Award\",\"datePublished\":\"2022-11-22T13:16:00+00:00\",\"dateModified\":\"2026-03-10T13:35:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/vetanco.com\/en\/vedevax-block\/\"},\"wordCount\":508,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/vetanco.com\/en\/vedevax-block\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/vetanco.com\/en\/wp-content\/uploads\/2024\/09\/Bioinnovo-finalista-premio-Empretec-1024x768-2.jpeg\",\"keywords\":[\"Banco Naci\u00f3n\",\"Bioinnovo SA\",\"Bovine Viral Diarrhea Virus\",\"BVDV\",\"Empretec\",\"INTA\",\"Vedevax BLOCK\",\"Vetanco\"],\"articleSection\":[\"Awards\",\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/vetanco.com\/en\/vedevax-block\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/vetanco.com\/en\/vedevax-block\/\",\"url\":\"https:\/\/vetanco.com\/en\/vedevax-block\/\",\"name\":\"Vedevax Block Vaccine finalist for the Empretec Award - Vetanco United States\",\"isPartOf\":{\"@id\":\"https:\/\/vetanco.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/vetanco.com\/en\/vedevax-block\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/vetanco.com\/en\/vedevax-block\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/vetanco.com\/en\/wp-content\/uploads\/2024\/09\/Bioinnovo-finalista-premio-Empretec-1024x768-2.jpeg\",\"datePublished\":\"2022-11-22T13:16:00+00:00\",\"dateModified\":\"2026-03-10T13:35:50+00:00\",\"author\":{\"@id\":\"https:\/\/vetanco.com\/en\/#\/schema\/person\/46afb38cfab0fe11bf52a9ded679bfcd\"},\"description\":\"The world\u2019s first targeted vaccine against the Bovine Viral Diarrhea Virus (BVDV), was one of 4 finalists in its category.\",\"breadcrumb\":{\"@id\":\"https:\/\/vetanco.com\/en\/vedevax-block\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/vetanco.com\/en\/vedevax-block\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/vetanco.com\/en\/vedevax-block\/#primaryimage\",\"url\":\"https:\/\/vetanco.com\/en\/wp-content\/uploads\/2024\/09\/Bioinnovo-finalista-premio-Empretec-1024x768-2.jpeg\",\"contentUrl\":\"https:\/\/vetanco.com\/en\/wp-content\/uploads\/2024\/09\/Bioinnovo-finalista-premio-Empretec-1024x768-2.jpeg\",\"width\":1024,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/vetanco.com\/en\/vedevax-block\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\/\/vetanco.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vedevax Block Vaccine finalist for the Empretec Award\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/vetanco.com\/en\/#website\",\"url\":\"https:\/\/vetanco.com\/en\/\",\"name\":\"Vetanco United States\",\"description\":\"Safe Products for Safe Food\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/vetanco.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/vetanco.com\/en\/#\/schema\/person\/46afb38cfab0fe11bf52a9ded679bfcd\",\"name\":\"julian\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/vetanco.com\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bc79426ed0651bb3545f906602e15ffcf6e4bdb7b02b2394b18705841d207f29?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bc79426ed0651bb3545f906602e15ffcf6e4bdb7b02b2394b18705841d207f29?s=96&d=mm&r=g\",\"caption\":\"julian\"},\"url\":\"https:\/\/vetanco.com\/en\/author\/julian\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vedevax Block Vaccine finalist for the Empretec Award - Vetanco United States","description":"The world\u2019s first targeted vaccine against the Bovine Viral Diarrhea Virus (BVDV), was one of 4 finalists in its category.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vetanco.com\/en\/vedevax-block\/","og_locale":"en_US","og_type":"article","og_title":"Vedevax Block Vaccine finalist for the Empretec Award - Vetanco United States","og_description":"The world\u2019s first targeted vaccine against the Bovine Viral Diarrhea Virus (BVDV), was one of 4 finalists in its category.","og_url":"https:\/\/vetanco.com\/en\/vedevax-block\/","og_site_name":"Vetanco United States","article_published_time":"2022-11-22T13:16:00+00:00","article_modified_time":"2026-03-10T13:35:50+00:00","og_image":[{"width":1024,"height":768,"url":"https:\/\/vetanco.com\/en\/wp-content\/uploads\/2024\/09\/Bioinnovo-finalista-premio-Empretec-1024x768-2.jpeg","type":"image\/jpeg"}],"author":"julian","twitter_card":"summary_large_image","twitter_misc":{"Written by":"julian","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/vetanco.com\/en\/vedevax-block\/#article","isPartOf":{"@id":"https:\/\/vetanco.com\/en\/vedevax-block\/"},"author":{"name":"julian","@id":"https:\/\/vetanco.com\/en\/#\/schema\/person\/46afb38cfab0fe11bf52a9ded679bfcd"},"headline":"Vedevax Block Vaccine finalist for the Empretec Award","datePublished":"2022-11-22T13:16:00+00:00","dateModified":"2026-03-10T13:35:50+00:00","mainEntityOfPage":{"@id":"https:\/\/vetanco.com\/en\/vedevax-block\/"},"wordCount":508,"commentCount":0,"image":{"@id":"https:\/\/vetanco.com\/en\/vedevax-block\/#primaryimage"},"thumbnailUrl":"https:\/\/vetanco.com\/en\/wp-content\/uploads\/2024\/09\/Bioinnovo-finalista-premio-Empretec-1024x768-2.jpeg","keywords":["Banco Naci\u00f3n","Bioinnovo SA","Bovine Viral Diarrhea Virus","BVDV","Empretec","INTA","Vedevax BLOCK","Vetanco"],"articleSection":["Awards","News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/vetanco.com\/en\/vedevax-block\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/vetanco.com\/en\/vedevax-block\/","url":"https:\/\/vetanco.com\/en\/vedevax-block\/","name":"Vedevax Block Vaccine finalist for the Empretec Award - Vetanco United States","isPartOf":{"@id":"https:\/\/vetanco.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vetanco.com\/en\/vedevax-block\/#primaryimage"},"image":{"@id":"https:\/\/vetanco.com\/en\/vedevax-block\/#primaryimage"},"thumbnailUrl":"https:\/\/vetanco.com\/en\/wp-content\/uploads\/2024\/09\/Bioinnovo-finalista-premio-Empretec-1024x768-2.jpeg","datePublished":"2022-11-22T13:16:00+00:00","dateModified":"2026-03-10T13:35:50+00:00","author":{"@id":"https:\/\/vetanco.com\/en\/#\/schema\/person\/46afb38cfab0fe11bf52a9ded679bfcd"},"description":"The world\u2019s first targeted vaccine against the Bovine Viral Diarrhea Virus (BVDV), was one of 4 finalists in its category.","breadcrumb":{"@id":"https:\/\/vetanco.com\/en\/vedevax-block\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vetanco.com\/en\/vedevax-block\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vetanco.com\/en\/vedevax-block\/#primaryimage","url":"https:\/\/vetanco.com\/en\/wp-content\/uploads\/2024\/09\/Bioinnovo-finalista-premio-Empretec-1024x768-2.jpeg","contentUrl":"https:\/\/vetanco.com\/en\/wp-content\/uploads\/2024\/09\/Bioinnovo-finalista-premio-Empretec-1024x768-2.jpeg","width":1024,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/vetanco.com\/en\/vedevax-block\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/vetanco.com\/en\/"},{"@type":"ListItem","position":2,"name":"Vedevax Block Vaccine finalist for the Empretec Award"}]},{"@type":"WebSite","@id":"https:\/\/vetanco.com\/en\/#website","url":"https:\/\/vetanco.com\/en\/","name":"Vetanco United States","description":"Safe Products for Safe Food","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vetanco.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/vetanco.com\/en\/#\/schema\/person\/46afb38cfab0fe11bf52a9ded679bfcd","name":"julian","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vetanco.com\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bc79426ed0651bb3545f906602e15ffcf6e4bdb7b02b2394b18705841d207f29?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bc79426ed0651bb3545f906602e15ffcf6e4bdb7b02b2394b18705841d207f29?s=96&d=mm&r=g","caption":"julian"},"url":"https:\/\/vetanco.com\/en\/author\/julian\/"}]}},"_links":{"self":[{"href":"https:\/\/vetanco.com\/en\/wp-json\/wp\/v2\/posts\/8588","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vetanco.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vetanco.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vetanco.com\/en\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/vetanco.com\/en\/wp-json\/wp\/v2\/comments?post=8588"}],"version-history":[{"count":2,"href":"https:\/\/vetanco.com\/en\/wp-json\/wp\/v2\/posts\/8588\/revisions"}],"predecessor-version":[{"id":13485,"href":"https:\/\/vetanco.com\/en\/wp-json\/wp\/v2\/posts\/8588\/revisions\/13485"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vetanco.com\/en\/wp-json\/wp\/v2\/media\/8590"}],"wp:attachment":[{"href":"https:\/\/vetanco.com\/en\/wp-json\/wp\/v2\/media?parent=8588"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vetanco.com\/en\/wp-json\/wp\/v2\/categories?post=8588"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vetanco.com\/en\/wp-json\/wp\/v2\/tags?post=8588"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}